ResMed Inc. Chairman and Chief Executive Officer Michael J. Farrell reported an insider transaction involving ResMed common stock on July 7, 2026. The Form 4 indicates that Farrell acquired shares through the exercise of stock options and sold shares in the market on the same date. The reported option-related transaction involved 4,991 shares at an exercise price of $146.34 per share. The filing’s explanatory note states that the options first became exercisable on the listed vesting date and vest in installments of one-third per year. Based on the reported exercise price, the total exercise cost for the 4,991 shares was approximately $730,383. Farrell also reported a sale of ResMed common stock at a weighted-average price of $218.5475 per share. The sale was executed in multiple trades at prices ranging from $216.772 to $219.700. Using the reported weighted-average price, the sale of 4,991 shares would represent gross proceeds of approximately $1.09 million before taxes, commissions or other expenses. The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on October 31, 2024. Such plans allow corporate insiders to establish prearranged trading instructions at a time when they are not in possession of material nonpublic information, helping distinguish planned diversification or liquidity transactions from discretionary trades. After the reported transaction, Farrell beneficially owned 471,214 shares of ResMed common stock. The filing was signed by Farrell on July 8, 2026, in his capacity as Chairman and CEO. Transaction codes were not visible in the provided filing text, but the reported activity reflects an option exercise paired with a stock sale.